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The formulation and delivery of the biologically 
active ingredients (AIs) (for example, agrochemicals 
and active pharmaceutical ingredients (APIs)) is 
an inherently interdisciplinary area of research 
and development. In this short review we discuss 
the evolution of AI and API delivery systems 
towards smart stimuli-responsive formulations 
with precisely controlled delivery for specific 
applications. We also highlight a few examples of 
such systems using AIs from Johnson Matthey’s 
controlled substance and API portfolio.
Introduction
The study of medicine has a long history, with the 
first records of physicians in Egypt (Hesy-Ra the first 
recorded male physician in ca. 2700 BCE; Peseshet 
the first recorded female physician in ca. 2400
 
 BCE) 
and important examples of prescriptions for 
medications (for example the Ramesseum medical 
papyrus in ca. 1800 BCE; the Kahun Papyrus in 
ca. 1800 BCE; the Ebers Papyrus in ca. 1550 BCE 
and the Edwin Smith Papyrus, 1500 BCE) also 
from Egypt. Important contributions to medicine 
have been made by researchers worldwide, with 
Nobel Prizes in Physiology or Medicine awarded to 
researchers from Africa, Asia, Australasia, Europe, 
North America and South America (see Table I).
While early medications were all natural 
products, the industry supporting the production 
of medications on large scales is inextricably 
linked to the chemical sciences, with companies in 
Europe (for instance, Merck & Co, Bayer and BASF 
in Germany; Ciba-Geigy, Roche and Sandoz in 
Switzerland; and Beecham Group, GlaxoSmithKline, 
Burroughs and Wellcome in the UK) and the USA 
(Eli Lilly and company, Pfizer and Squibb) making 
important early contributions (1).  While the scale 
of the industry and complex developments in 
regulations and mergers are outside the scope of 
this review, it is noteworthy that the industry has a 
hugely beneficial economic impact (worldwide the 
pharmaceutical industry employs millions of people 
and has a revenue that exceeded US$1000 billion 
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Table I  First Examples of Nobel Laureates in Physiology or Medicine from Specific  
Geographic Regions
Year Laureate Country Justification Geographic region
1901 Emil Adolf von Behring Germany For work on serum therapy Europe
1902 Ronald Ross UK, India For work on malaria Europe, Asia
1923 Fredrick Grant Banting, John James Rickard Macleod
Canada, 
UK For the discovery of insulin
North America, 
Europe
1945 Alexander Fleming, Ernst Boris Chain, Howard Waiter Florey
UK, 
Australia For the discovery of penicillin
Europe, 
Australasia
1947 Carl Ferdinand Cori, Gery Theresa Cori, Bernardo Alberto Houssay
USA, 
Argentina
For their discovery of the course 




1951 Max Theiler South Africa
For discoveries concerning yellow 
fever and how to combat it Africa
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every year from 2014) and health and societal 
impacts (such as improvements in life expectancy).
The success of this industry is contingent 
on significant investment in research and 
development (R&D) processes (2). The bioactive 
molecule discovery process involves identification 
of lead compounds plus design and synthesis of 
variants to screen their therapeutic potential. The 
bioactive development process is used to establish 
the suitability of the bioactive manufacturing 
process, including: appropriate design of 
synthetic route answering such questions as 
whether it is affordable and if the building blocks 
are available from a reliable source, identification 
and toxicology of intermediates and impurities 
(3). Early stage bioactive discovery (technology 
readiness levels (TRLs) 1–4) is carried out by 
researchers in academia and industry; late 
stage development (particularly to increase 
the selectivity, bioavailability and therapeutic 
efficiency of the compounds) (4) is most often 
carried out by industry, with formulation studies 
and in vitro and in vivo validation studies carried 
out either in house or outsourced to an academic 
or industrial contractor prior to clinical trials in 
collaboration with health services (for example, 
the National Health Service (NHS) in the UK) 
and regulatory bodies depending on the specific 
market (5). The bioactive molecule industry is 
constantly evolving to deal with national and 
international regulations and the scrutiny of 
healthcare organisations (6). New synthetic 
strategies and analytical and computational 
techniques allow for the exploration of an ever-
wider range of bioactives which pose both 
challenges and opportunities for companies 
active in this highly competitive market.
The remainder of this review will focus on 
the formulation of AIs in agrochemical and 
pharmaceutical formulations (also known as 
active substances, bioactives, bulk actives, APIs 
and drugs), primarily for application to humans 
(cognisant of the vast market for formulations 
of bioactives for agrochemical and veterinary 
applications and different requirements in terms of 
formulation methodology and regulations).
API Delivery System Development
Organisms are controlled on the cellular level by 
a multitude of bioactive molecules. It is highly 
likely that throughout an organism’s lifetime one 
of these systems will falter due to disease or injury 
and a therapeutic API could be employed to aid in 
the recovery of normal function (7). The complex 
nature of an organism’s cells and physiology 
provide many opportunities for API intervention 
(for instance, specific intracellular functions) 
when required to affect the desired response (7). 
APIs have a therapeutic window (as depicted in 
Figure 1). Below the therapeutic window we 
observe the subtherapeutic region in which an 
API is ineffective at providing the desired effect, 
whereas above the therapeutic window unwanted 
side effects and toxicity may be observed (8).
The formulation of APIs to deliver quantities 
of the API within the therapeutic regime is of 
key importance to their clinical translation and 
success. Formulations can be divided into two 
broad categories: non-synthetic formulations (the 
most common) where the API is used unmodified 
in combination with other ingredients in order 
to achieve the desired effect (see Table II for 
examples);  or synthetic formulations, where 
the API is synthetically modified to impart the 
desired properties, for example, prodrugs (14). 
Formulations need to be tailored to suit their route 
of administration such as inhalation, injection, 
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oral or transdermal. For humans, oral intake is by 
far the most popular, providing fast release, cost 
effectiveness and relatively high patient compliance 
(15). The fast release provided by traditional 
methods of API delivery such as inhalation, 
injection, oral and transdermal can be beneficial for 
pain relief, however they often require the patient 
to take a relatively high dose of an API to ensure 
a small amount of the API reaches the desired 
location to elicit the desired therapeutic response 
(16). This may also result in issues related to 
API clearance from the body (metabolised or 
excreted via the renal system) which can limit 
the duration the API is within the therapeutic 
window. Other factors including the biological and 
physicochemical  properties of the APIs (such as 
solubility and absorption) (17, 18) and patient 
compliance (of growing importance with ageing 
populations worldwide) highlight the market need 
for controllable API delivery systems for medical or 
veterinary applications, similarly for agrochemical 
applications (19). Indeed, API delivery systems 
that reduce the number of administrations required 
offer potentially significant economic, health and 
societal impacts (20).
Researchers based in industry and academia 
have therefore invested significant effort in 
the development of API delivery systems to 
address these issues, which are often classified 
generationally, with first generation delivery 
systems developed between 1950–1980, 
second generation delivery systems developed 
between 1980–2010 and third generation 
delivery systems developed from 2010 
onwards (21–23). The first case of controlled 
API release was published by Smith, Kline & 
French, USA, when they demonstrated the ability 
to release dextroamphetamine (Figure 2) over 
a 12 h period in 1952 (24). The success of this 
breakthrough prompted an investigation of new 
controlled API delivery systems designed to reduce 
intake to once or twice a day and mechanisms of 












































































































































Fig. 2. Examples of chemical structures





Light Photodynamic therapy (10)
Electricity Electroconvulsive therapy (11)
Ultrasound Sonograms (12)
Infrared Thermography (13)
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dissolution) (25). By understanding these release 
mechanisms it was possible to begin to control 
the physicochemical characteristics of API delivery 
systems and thereby the release profiles of the 
APIs. While first generation API delivery systems 
delivered their payloads at a predetermined rate 
that was often short and did not account for 
patient needs or varying physiological conditions 
(8), second generation API delivery systems are 
characterised by attempts to control the level 
of API within target tissues above the minimum 
effective level for prolonged periods. The 
maintenance of the minimum effective level is 
important not only to ensure the benefit of the 
API to the patient over an extended period of 
time, but also to prevent the onset of side effects 
and immune responses. An interesting example 
of this is a formulation capable of sustained 
release of quetiapine (Figure 2, which is used 
in the treatment of schizophrenia) that has 
reduced the administration regime to a single 
dose per day, diminishing problems with patient 
compliance (26, 27).
Second generation API delivery systems also 
include examples capable of delivering high 
molecular weight APIs (peptides, proteins and 
DNA) potentially from hydrogel- or nanoparticle-
based API delivery systems, that were optionally 
cell-targeted or stimuli-responsive (25). The third 
generation API delivery systems are characterised 
by efforts to: deliver poorly soluble APIs; 
tightly control release kinetics (for example via 
application of one or more external stimuli); and 
overcome biological barriers (such as the blood-
brain barrier) (23, 25).
An ideal API delivery system would be a source of 
a specific amount of API to a precise location with 
temporal control, thereby allowing maintenance of 
a minimum effective level of the API for the duration 
required to have its therapeutic effect (illustrated 
in Figure 1) (28). Different situations require 
different API release profiles and application- or 
patient-specific API delivery profiles are desirable 
for the medical, veterinary and agrochemical 
industries (29).
API delivery systems incorporating polymers 
have been developed for first, second and third 
generation of delivery systems and polymers 
of various architectures are key components 
of both non-synthetic (such as aerosols, 
dispersions, emulsions, foams and suspensions) 
and synthetic formulations (for instance, as a 
polymer prodrug). The pioneering research of 
Robert Langer and coworkers underpins the 
development of polymer- based drug delivery 
systems (DDS) in academic and industrial settings 
(30–32). Polymer chemistry and engineering 
to tailor the structures of polymers for specific 
applications is an area of intense ongoing research 
interest (33), particularly with a view to developing 
API delivery systems that provide control over the 
quantity, location and time of API delivery (34).
Polymer-based API delivery systems can enhance 
the duration of activity for APIs with short half-
lives (28). API delivery systems that encapsulate 
a payload of API and break down at a predictable 
rate can be utilised for a variety of therapeutic 
agents, particularly when displaying a moiety 
that targets the API to specific cells or tissues 
(35). Poly(ethylene glycol) (PEG, Figure 2) is a 
polymer often conjugated to macromolecular APIs 
(commonly known as PEGylation) (36) to enhance 
their half-lives by reducing their rate of clearance 
via the renal system and eliciting minimal 
inflammatory response (37).
The utilisation of biodegradable and bioerodible 
polymers such as poly(caprolactone) (PCL, 
Figure 2), poly(D,L-lactic-co-glycolic acid) 
(PLGA, Figure 2) and PEG that respond to 
enzymes such as esterases and lipases are now 
very popular as a result of their biocompatibility in 
vivo reducing the immune response and averting 
systemic toxicity (38, 39). Cisplatin (Figure 2) 
(40) is a common anticancer API that has proved 
effective in the treatment of a variety of tumours 
however its inherent toxicity and resistance 
limitations have prevented the full potential of 
this API being reached (41). A recent study into 
the construction of platinum(IV)-encapsulated 
prostate-targeted nanoparticles of PLGA-PEG 
functionalised with prostate-specific membrane 
antigen (PSMA) targeting aptamers was found 
to help optimise the delivery of a lethal dose of 
cisplatin to prostate cancer cells (41). The use of 
these polymeric agents in this manner not only 
provides controlled breakdown of the DDS giving 
slow release of the API but also provides specific 
targeting of cancer cells.
Other physicochemical triggers (for instance, 
pH) are also of interest for API delivery 
systems. Cancer cells are associated with a 
lower pH (normally ca. 5/6) than normal cells 
thus making pH sensitive API delivery systems 
desirable as damage to healthy cells can be 
minimised (42). Likewise, the acidic milieu 
within dental caries-producing biofilms are 
another situation in which pH can be a useful 
trigger for oral drug delivery (43).
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API Delivery Systems for Specific 
Contexts
Oral API Delivery Systems
Oral administration of APIs necessitates the stability 
of the API and its respective acidic and basic 
components in the digestive tract and effective 
permeation of cell membranes (44). Ion-exchange 
systems have been investigated for their ability 
to act as API delivery systems, wherein once the 
API reaches the gastrointestinal tract the body’s 
salts displace the API allowing it to pass through 
the cell membrane in a controlled manner (20). 
However, human physiology makes API delivery 
via gastrointestinal (GI) tract challenging (45). The 
short GI transit time (ca. 12 h) makes the delivery 
of macromolecular therapeutics such as proteins 
and nucleic acids difficult (45). The limitations 
of API delivery in the GI tract (44) have helped 
to shape the development of polymer-based API 
delivery systems to deliver macromolecules such 
as insulin orally or via inhalation (46, 47).
An ideal API delivery system would allow a patient 
to monitor and administer drugs (such as insulin) 
on demand with control over the dose and no need 
for invasive injections. Variations of these are 
currently being developed for the self-regulated 
treatment of diabetes (48).
Transdermal API Delivery Systems
Transdermal patches were amongst the first 
systems to be available to patients with APIs being 
attached to an adhesive patch before delivering 
a specific dose through the patient’s skin and 
into the bloodstream (49). Transdermal patches 
enable controlled release via a porous membrane 
slowly releasing an API from a reservoir within 
the patch. The first transdermal patch was FDA 
approved in 1979 for the delivery of prescription 
API scopolamine (Figure 2) for the treatment 
of motion sickness (50). Nowadays, many APIs 
are administered via transdermal patches (for 
example, Daytrana, EMSAM, Exelon and 
fentanyl, Figure 2) covering a wide range of 
medical conditions from Alzheimer’s to attention 
deficit hyperactivity disorder (ADHD) (51). 
Whilst API delivery from transdermal patches 
is effective, the skin is a barrier to entry from 
external bodies which results in a high proportion 
of the API being prevented from entering the 
body and a reduced therapeutic efficiency (49). 
One solution to this problem is the utilisation of 
chemical enhancers (49) to alter the permeability 
of an API, for example, the skin permeability of 
oestradiol (Figure 2) can be increased twenty-
fold via formulation with ethanol (52). A common 
side effect of the use of chemical enhancers is 
skin irritation at the site of the patch which may 
make the use of the enhancer non-viable. Another 
method is to chemically modify the structure of the 
API to improve its permeability; however, this can 
be difficult, expensive and time consuming (53). 
The use of arrays of microneedles for transdermal 
delivery is increasingly popular because of their 
broad applicability and minimal pain (54).
The use of microneedles in drug delivery began 
in the 1990s as a result of the emergence of 
microfabrication techniques that enable their 
manufacture (55). Microneedles are used in a 
variety of medical systems including skin pre-
treatment for increased permeability, drug coated 
needles and drug encapsulated needles (55). 
Microneedles are now widespread in drug delivery 
having shown the ability to give controlled release 
of a wide range of low molecular weight drugs 
and vaccines (55). The delivery of the influenza 
vaccine using a microneedle is common in modern 
medicine (56). Microneedle delivery depends on 
a variety of factors including skin permeation, 
drug stability, drug storage and patient response 
(55). This emerging field of medicinal chemistry 
shows great promise in forwarding the field of 
drug delivery.
Injectable and Implantable API 
Delivery Systems
Injectable and implantable API delivery systems 
are particularly useful for conditions requiring the 
delivery of APIs to specific sites within the organism. 
Many APIs suffer from an inability to reach the 
required site of action due to a biological barrier 
(for example, the blood-brain barrier). Parkinson’s 
disease caused by dopamine deficiency cannot be 
treated by administration of dopamine because it 
does not cross the blood-brain barrier, however, the 
prodrug levodopa (Figure 2) is capable of crossing 
the blood-brain barrier after which it is metabolised 
to dopamine (Figure 2) (57). 
Likewise, <2% of the administered dosage of 
naltrexone (Figure 2), an API used in the treatment 
of opioid dependence reaches the brain and 
naltrexone-polymer conjugates can increase the 
amount of API working at the site of action resulting 
in US Food and Drug Administration (FDA) approval 
for use for the treatment of alcohol dependence 
(2006) and opioid dependence (2010) (58).
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Implanting API delivery systems at or near the 
desired site helps to maximise local delivery and 
minimise undesirable side effects. A polymer-based 
API delivery system known as Ocusert which controls 
the release of pilocarpine (Figure 2) and reduces 
pressure in the eyes (59); implantation of pilocarpine 
encapsulated between two polymer membranes 
controlled the release at a rate of 20 mg h–1 for 
up to a week (59). Several polymeric versions of 
the Ocusert delivery system exist, all capable of 
delivering pilocarpine in a controlled manner with 
differing release profiles. Early uses of this system 
were limited by poor biodegradability, however, new 
formulations of biodegradable polymers have helped 
to improve degradation profiles (60).
Biodegradable polymers (such as poly(anhydrides) 
and polyesters) used for polymer-based API 
delivery systems can slowly degrade and release 
APIs (for example, carmustine (Figure 2) a 
chemotherapeutic treatment for brain cancer) and 
carmustine-loaded polyanhydride films directly at 
the tumour site were shown to significantly improve 
patient survival rates when treating glioblastoma 
multiforme (61). 
PGLA has also been used in the controlled 
delivery of the API apomorphine (Figure 2) which 
is used in the treatment of Parkinson’s disease 
(62). Apomorphine has poor oral availability and a 
short half-life, resulting in multiple administrations 
being required which limits its widespread usage, 
therefore controlled release methods are used to 
overcome this shortcoming (62). The use of PGLA 
prevents the burst release of apomorphine and 
increases longevity of the API within the target 
tissues (62). This system demonstrated controlled 
release of the API over ten days, releasing 90% of 
the payload.
Stimuli-Responsive API Delivery 
Systems
The investigation of smart devices in medicine has 
probed the use of API delivery systems that can 
control API release using an external stimulus or 
by interactions between the API delivery systems 
and changes in their environment. By implanting 
a biocompatible device within the patient and 
then triggering API release externally, the patient 
would be provided with the therapeutic benefit over 
an extended period of time. An ideal API delivery 
system would allow control of the dosage, timing, 
duration and site of API release, resulting in delivery 
of the therapeutic agent in a remote and non-
invasive manner. A range of stimuli can be used to 
trigger API release including pH, infrared (IR) (63), 
ultraviolet (UV)-visible light (64, 65) magnetism 
(66), temperature (67), ultrasound (68), electric 
fields (69) and radiation (70). Many of these stimuli 
are already utilised in clinically translated API delivery 
systems (Table II). The development of API delivery 
systems that respond to these stimuli and provide 
the controlled release of loaded APIs potentially 
improves treatment efficiency and diminishes or 
prevents the onset of side effects. There are API 
delivery systems that respond to multiple stimuli 
to further improve selectivity for specific functions 
(71), see below for a fuller discussion.
Another emerging aspect of formulation science 
involves the use of shape memory materials 
(SMMs). SMMs demonstrate plastic deformation 
when stimulated by an external stimulus and 
return to their original shape upon removal of the 
stimuli (72). Shape memory polymers (SMPs) are 
stimuli responsive compounds which are able to 
demonstrate mechanical action in response to a 
range of stimuli depending on the material make up. 
SMPs offer a range of advantages including; wide 
glass transition states, tailored stiffness, high shape 
recovery, high elastic deformation, biodegradability, 
biocompatibility and low thermal conductivity 
(72). The ability of these materials to assume a 
specific shape upon triggering can be utilised for 
drug delivery. PCL and poly(lactide) (Figure 2) 
are often utilised in medical SMPs as they have 
distinctive glass transition states and are inherently 
biodegradable and biocompatible (73). The use of 
these polymers in SMPs can assist in drug delivery 
via two mechanisms: either the shape recovery of 
the polymer enhances drug release or the polymer 
facilitates delivery of the drug delivery device to 
the body in a minimally invasive manner (73). The 
incorporation of a drug into a SMP delivery system 
has been demonstrated to affect performance of the 
DDS however controlled release is still possible. The 
use of SMPs in urethral stents has been demonstrated 
using the SMP as a method of controlled release 
of anti-inflammatory drugs (74). This method 
demonstrated the ability of SMPs to show controlled 
release of a drug and upon completion degradation 
into non-toxic products (74). This example highlights 
the potential use of SMPs in drug delivery and wider 
medicinal applications (75).
Light-Responsive API Delivery 
Systems
Light triggered API delivery systems are very 
popular in the literature due to their ability to 
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provide temporal and spatial control, functioning 
via various mechanisms including photochemical, 
photoisomerisation and photothermal (76). 
Photodynamic therapy (PDT) is one of the most 
well-established techniques and uses light in 
the UV-visible spectrum to treat skin and throat 
cancers (77). PDT is less effective when attempting 
to affect deeper set tumours such as prostate and 
liver cancers for which light in the IR spectrum is 
preferable as a result of its relatively low absorption 
by mammalian tissues (63).
Photochemical API delivery systems release a 
therapeutic payload upon covalent bond cleavage 
in response to light irradiation (76). An example of 
such chemistry is the cleavage of an o-nitrobenzyl 
ester derivative releasing a carboxylic acid 
(Figure 3). The carboxylic acid-displaying molecule 
was released over several hours at surface power 
of 1.3 mW cm–2, however when increasing the 
power to 20 mW cm–2 release was only observed 
over 5 min (78). This system demonstrates a high 
degree of control that shows promise in being 
utilised in API delivery studies.
A library of photo-responsive units have been 
explored for API delivery including coumarin, 
pyridylmethyl esters and porphyrins, all of which 
contain readily cleavable covalent bonds (79). 
Photo-responsive API delivery systems function 
on the requirement of light with a wavelength 
that possess sufficient energy per photon to affect 
the breakage of covalent bonds (80), making UV 
(81) and visible light (79) popular triggers. One of 
the most prevalent problems with light triggered 
API delivery systems is the relatively poor tissue 
penetration of UV and visible light, this has been 
addressed by the development of near-infrared 
(NIR) API delivery systems (82). NIR is only 
fractionally adsorbed by biological tissues thus 
allowing it to trigger API release in deeper areas 
of the body (82). Almutairi et al. report the use 
of a UV responsive nanoparticle DDS in which 
nintedanib (Figure 2), a drug used in the treatment 
of idiopathic pulmonary fibrosis, is released over 
ten weeks (83). The nanoparticles were shown to 
be biocompatible with no adverse effects observed 
despite the extended period of implantation (83).
Photo-responsive hydrogel-based API delivery 
systems (84) offer the opportunity to deliver 
sensitive bioactive macromolecules (84) and 
minimise the body’s immune response. A 
recent trend in the literature points towards the 
development of systems that do not require the 
use of UV as a result of the risk it poses to the skin 
and eyes. The use of NIR and visible light triggered 
systems are increasingly popular in photochemical 
API delivery due to reduced risk associated with 
these triggers (85).
Whilst a great deal of progress has been made 
in the field of photochemical API delivery many 
problems still persist and must be overcome before 
these systems are fully utilised in modern medicine. 
Early attempts at photochemical triggering often 
resulted in one effective dosage of the API before 
the system is empty, however new innovative 
systems have demonstrated pulsatile delivery 
with few adverse effects. Tissue penetration is 
still a problem in this field with visible light-based 
systems limited to the skin, throat and nose (63). 
As with all new systems being introduced to the 
body, biocompatibility is a huge stumbling block. 
Even the most biocompatible systems generate 
some form of immune response, sometimes in 
the form of inflammation but others can be more 
serious and so systems must be vetted fully before 
use. Despite these problems, photochemical API 
delivery remains a very popular research area with 
huge progress being made throughout this field.
Electro-Responsive API Delivery 
Systems
Early attempts to develop stimuli responsive 
systems included the development of conducting 
polymers which were theorised to be able to release 
an API upon triggering with an electrical stimulus. 
Polypyrrole (PPy) in its conducting (oxidised) form 
allows oppositely charged ions to be doped into 
the polymer backbone which was pioneered by 
the Miller Group in 1984, who demonstrated their 
ability to release glutamate ions (Figure 2) via 
the reduction of PPy (Figure 4) films (86). The 
cationic PPy is doped with anionic or neutral API 
molecules. When an electric current is applied to 
the system the polymer changes redox state and 
the API is released in order to charge balance the 
system (87).
The sensitivity of electroactive species can be 
manipulated to create a range of API release 
Fig. 3. Photochemical cleavage of an o-nitrobenzyl 
ester yielding an o-nitrosobenzaldehyde derivative 
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profiles through redox switching. Despite the 
widespread usage of PPy as an API delivery agent 
it is difficult to process due to its poor solubility in 
most solvents. Many attempts have been made to 
improve the solubility of PPy with limited success 
(88). PPy is also non-biodegradable and therefore 
can be difficult to remove from the patient’s 
system once all the loaded API has been used (89). 
The success of utilising PPy films as API delivery 
agents prompted an investigation into other 
polymers such as polyaniline (PANi, Figure 2) (90) 
and poly(3,4-ethylenedioxythiophene) (PEDOT, 
Figure 2) (91) with varying degrees of success. 
The biocompatibility of the polymers and the 
amount and molecular weight of API that can be 
loaded onto these films are areas of current research 
(92, 93), as is the generation of biodegradable 
versions (94, 95).
Multi-Responsive API Delivery 
Systems
Whilst single stimuli responsive systems are very 
useful, they are restricted to certain release profiles 
based on the stimuli in question. The complex 
nature of the human body and the conditions which 
affect it often require additional more complex 
solutions than single stimuli-responsive DDS. 
Multi-stimuli responsive DDS are being explored 
for their ability to create more varied release 
profiles, providing an improvement in tuneability 
and selectivity versus single responsive systems 
(96). In theory multi-responsive DDS allow for the 
treatment of a wider range of complex conditions 
by regulating release by one or more stimuli based 
on patient needs (96). 
When constructing multi-responsive DDS separate 
units, each of which is responsive to a specific 
stimulus, are blended together without affecting 
each unit’s responsiveness. Several systems are 
currently in development based on the ability of 
one stimulus to act as a targeting moiety whilst 
the other stimuli are responsible for producing a 
response in the desired tissue.
pH is one of the most commonly used stimuli in dual 
responsive DDS. The ability of these systems to be 
selective based on the targeting of the lower pH of 
cancer cells makes them desirable in modern cancer 
treatments (97–100). pH is often combined with a 
variety of other stimuli including light, electricity 
and magnetism to create a desired response in 
cancerous tissues. pH and light responsive materials 
are popular dual responsive DDS. Nie et al. have 
demonstrated the ability of these systems to 
show controlled release of the chemotherapy 
agent doxorubicin hydrochloride (Figure 2) via 
photothermal drug release (101). The use of a pH 
responsive group ensured selectivity towards cancer 
cells over healthy cells with an NIR responsive group 
providing photothermal release of doxorubicin 
hydrochloride in a controlled manner (101).
Dual responsive DDS which incorporate multiple 
stimuli capable of creating the desired drug release 
response are less common, however several 
examples exist in the literature. Argouz et al. have 
developed such a system with the use of sodium 
alginate gel beads in a pH or magnetic drug release 
system (102). In this system pH sensitive sodium 
alginate is combined with methyl cellulose which 
has shown to be responsive to magnetic fields. 
Sodium alginate is a biodegradable, biocompatible, 
non-toxic polysaccharide and can be readily 
modified making it a useful tool in drug delivery 
(103). It has been combined with chitosan, pectin 
and gelatin for use in drug delivery with all systems 
displaying a high degree of biocompatibility (103). 
The resulting material has demonstrated the ability 
to show controlled release of the anticancer drug 
5-fluorouracil (Figure 2) over extended periods 
of time (102). This system is comprised of both a 
targeting stimulus and two active delivery stimuli 
providing a high degree of impact when attempting 
to affect cancer tissues. 
Kyriakides et al. took a different approach to 
multi-responsive DDS being able to generate 
constructs via simultaneous electrospinning and 
electrospraying, generating compartmentalised 
storage of multiple drugs (104). The use of this 
method provides a PCL fibre structure with a 
hyaluronic acid core, allowing drugs to be loaded in 
the polymer film (104). Further studies have shown 
the ability to trap other spheres of drug within an 
electrospun mat, allowed for delivery of multiple 
drugs with differing solubilities demonstrating 
various release profiles (104). A minimal immune 
response was found when using pirfenidone 
(Figure 2), an anti-fibrotic drug, in one of the 
release compartments (104).
Multi-responsive systems are becoming more 
prevalent in the literature with many systems 
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demonstrating effectiveness in drug delivery, 
particularly when attempting to affect cancerous 
tissues. This field will continue to grow as scientists 
find more ways to incorporate more stimuli into 
existing systems, providing ample opportunity to 
treat a variety of conditions and improve patient 
care. Some examples for APIs displayed in Figure 5 
and Figure 6 are highlighted in Table III. 
Future Outlook and Conclusions
Significant progress has been made in the field 
of API delivery over the past sixty years and the 
scope of controlled API delivery systems has 
greatly increased. Many challenges still remain in 
this field, such as delivering APIs to specific cells, 
targeting genes and designing systems to cross 
complex barriers such as the blood-brain barrier 
(42). New materials are being developed aimed 
at improving biocompatibility, generating new 
release profiles and improving patient care (142). 
Continued investment and effort in this field will 
lead to the development of API delivery systems 
capable of the delivery of APIs to specific tissues to 
the benefit of patients and the healthcare industry. 
Advancements in the field of API delivery and 
controlled release have had a direct impact on 
other fields of chemistry such as synthetic and 
polymer chemistry, chemical engineering, materials 
science, chemical biology and bioengineering (33). 
Many API delivery systems exist generating a 
variety of release profiles and targeting different 
conditions. Conditions can now be treated at the 
required site of action leading to more effective 
treatments and broadening our understanding of 
biological mechanisms that affect diseases. Despite 
the increase of treatments and the deepening of 
our understanding of API release, clinical needs 
are still unmet and many challenges still remain. 
Administrative demand has forced new methods 
of API delivery to be formulated that protect 
sensitive molecules as well as targeting deep set 
regions of the body which are often unreachable 
by oral delivery systems. Advances in synthetic 
chemistry have allowed for the development of 
new classes of therapeutic agents that aim to 
address administrative demands and in tandem 
with materials science, have allowed release 











































































































Fig. 5. Examples of APIs formulated in controlled delivery systems highlighted in Table III
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Silodosin Sorafenib Travoprost Trientine Venetoclax
Phytonadione
Table III Examples of API Formulations
API CAS number Shown in figure number Examples Reference 
Afatinib dimaleate 850140-72-6 Figure 5 Injection (105)
Alprostadil 745-65-3 Figure 5 N/A –
Apomorphine hydrochloride 41372-20-7 Figure 2 Various (106, 107)
Atropine sulfate 5908-99-6 Figure 5 Inhaler (108)
Auranofin 34031-32-8 Figure 5 Oral (109)
Bimatoprost 155206-00-1 Figure 5 Implant (110)
Bromfenac sodium 120638-55-3 Figure 5 N/A –
Carboplatin 41575-94-4 Figure 5 Oral (111)
Carmustine 154-93-8 Figure 2 Implant (112)
Cisplatin 15663-27-1 Figure 2 Various (113, 114)
Crisaborole 906673-24-3 Figure 5 N/A –
Decitabine 2353-33-5 Figure 5 Various (115)
Diprenorphine 14357-78-9 Figure 5 N/A –
Dofetilide 115256-11-6 Figure 5 Oral (116)
Edrophonium chloride 116-38-1 Figure 5 Various (117, 118)
(Continued)
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Table III Continued
API CAS number Shown in figure number Examples Reference 
Ethacrynic acid 58-54-8 Figure 5 Various (119)
Ethacrynate sodium 6500-81-8 Figure 5 Various (103)
Fluvoxamine maleate 54739-20-7 Figure 5 Oral (120)
Isoproterenol hydrochloride 51-30-9 Figure 6 Oral (121)
Ivabradine hydrochloride 148849-67-6 Figure 6 Implant (122)
Lenalidomide 191732-72-6 Figure 6 Oral (123)
Lurasidone hydrochloride 367514-88-3 Figure 6 Oral (124)
Miglustat 72599-27-0 Figure 6 Inhaler (125)
Naloxone hydrochloride dihydrate 51481-60-8 Figure 6 Hydrogel (126)
Naltrexone hydrochloride 16676-29-2 Figure 2 Various (127)
Nilotinib 641571-10-0 Figure 6 N/A –
Nintedanib 656247-17-5 Figure 6 Various (128, 83)
Nitisinone 104206-65-7 Figure 6 Various (129, 130)
Phytonadione 84-80-0 Figure 6 Various (131)
Pirfenidone 53179-13-8 Figure 2 Various (132, 133)
Pomalidomide 19171-19-8 Figure 6 Various (134)
Roflumilast 162401-32-3 Figure 6 Various (135, 136)
Silodosin 160970-54-7 Figure 6 N/A –
Sorafenib 284461-73-0 Figure 6 Various (137–139)
Travoprost 157283-68-6 Figure 6 Implant (110, 140)
Trientine hydrochloride 38260-01-4 Figure 6 Oral (141)
Venetoclax 1257044-40-8 Figure 6 N/A –
The field of controlled delivery of APIs is 
broadening with new emerging concepts such as 
systems based on three-dimensional (3D) printed 
technologies and gene delivery systems becoming 
useable alternatives (143).
It is important that we continue to strive for a 
greater understanding of the human body and 
the DDS we are trying to input. We can begin to 
exploit expressions exhibited by specific diseases 
to improve targeting and tailor our systems to 
maximise therapeutic efficiency. The field of 
API delivery forms the intersection of chemistry, 
materials science, medicine and bioengineering. 
This has proved to be an extremely fruitful area 
with wide scope for exciting future work.
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